Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Mark Harbinson"'
Autor:
Mark Harbinson, Peter McKavanagh, Rejina Verghis, Patrick Donnelly, Peter A Ball, A. Agus, Tom Trinick, Gerard Walls, Lisa Lusk
Publikováno v:
Heart. 102:356-362
Objective To assess the cost-effectiveness of cardiac CT compared with exercise stress testing (EST) in improving the health-related quality of life of patients with stable chest pain. Methods A cost–utility analysis alongside a single-centre rando
Publikováno v:
Heart. 102:A138.1-A138
Introduction Chronic Kidney Disease (CKD) is a risk factor for contrast induced nephropathy (CIN), defined as an increase in serum creatinine of >25% from baseline or a delta rise of >26.5 µmol/L within 48 h. Early diagnosis of CIN requires validate
Publikováno v:
Heart. 102:A2.2-A2
Background Successful recanalisation of chronic total occlusion (CTO) is associated with improved mortality but a strong correlation with burden of ischaemia and symptoms is lacking. Myocardial perfusion reserve (MPR) by first-pass perfusion cardiac
Publikováno v:
Heart. 101:A7.1-A7
Background Viability assessment prior to revascularisation at our institution is largely requested for patients with severely impaired left ventricles (LV). This study however aims to review the outcomes of those patients with preserved or mildly imp
Publikováno v:
Heart. 101:A6-A6
Background Identifying patients with ischaemic left ventricular dysfunction that would benefit from revascularisation is challenging. The aim of this study was to investigate the role of cardiovascular magnetic resonance (CMR) imaging in the decision
Autor:
Peter J Scott, Mark Harbinson, A.A.J. Adgey, Daniel Guldenring, Dewar D. Finlay, Michael J Daly
Publikováno v:
Heart. 99:A31.1-A31
Background Epicardial potentials (EP) derived from body surface potentials using a thoracic volume conductor model (TVCM) improve acute myocardial infarction (AMI) diagnosis. In this study, we compared EP derived from the 80-lead body surface potenti
Publikováno v:
Heart. 98:A6.2-A6
Introduction Pulmonary hypertension (PH) is characterised by elevated pulmonary arterial pressures, inappropriate apoptosis and vascular remodelling. Animal models fail to replicate such cellular changes. Current therapies target several mediators in
Publikováno v:
Heart. 98:A5.1-A5
Introduction Elevated blood levels of cardiac troponin (cTn) released during myocardial ischaemia/infarction define acute coronary syndrome (ACS). However, cTn is not detectable for 3–4 h after symptom onset. The peptide Calcitonin Gene Related Pep
Publikováno v:
Heart. 98:A5.3-A6
Introduction HER2-positive breast cancer therapy with Trastuzumab, typically with the anthracycline, Epirubicin, increases survival but may decrease left ventricular ejection fraction (LVEF) asymptomatically; serial echocardiograms are needed. Increa
Autor:
David Bell, Matthew Ferguson, Stephen McAleer, Anna O’Regan, Mark Harbinson, Malcolm Campbell, Liz Donaghy
Publikováno v:
Heart. 98:A6.1-A6
Introduction Intermedin (IMD) protects the rodent cardiovascular system from ischaemia. Reperfusion after acute coronary syndrome augments cellular damage. It is not known if IMD benefits human cardiovascular cells during reperfusion injury. Aims To